Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We are amid the historic coronavirus infectious disease 2019 (COVID-19) pandemic. Imbalances in the accessibility of vaccines, medicines, and diagnostics among countries, regions, and populations, and those in war crises, have been problematic. Nanobodies are small, stable, customizable, and inexpensive to produce. Herein, we present a panel of nanobodies that can detect the spike proteins of five SARS-CoV-2 variants of concern (VOCs) including Omicron. Here we show via ELISA, lateral flow, kinetic, flow cytometric, microscopy, and Western blotting assays that our nanobodies can quantify the spike variants. This panel of nanobodies broadly neutralizes viral infection caused by pseudotyped and authentic SARS-CoV-2 VOCs. Structural analyses show that the P86 clone targets epitopes that are conserved yet unclassified on the receptor-binding domain (RBD) and contacts the N-terminal domain (NTD). Human antibodies rarely access both regions; consequently, the clone buries hidden crevasses of SARS-CoV-2 spike proteins that go undetected by conventional antibodies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257560 | PMC |
| http://dx.doi.org/10.1038/s42003-022-03630-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeted degradation of the HPV oncoprotein E6 reduces tumor burden in cervical cancer.
Mol Ther
August 2025
Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. Electronic address:
Human papillomavirus (HPV) remains a global health burden, yet there are no targeted therapies for HPV-related cancers. The HPV E6 protein is essential for tumorigenesis and immune evasion, making it an attractive target for antiviral drug development. In this study, we developed an E6-targeting proteolysis targeting chimera (PROTAC) that inhibits the growth of HPV tumors.
View Article and Find Full Text PDFAllosteric Antibody Modulation of EGFR Activity: Bridging Experiment and In Silico Modeling.
J Mol Biol
July 2025
Antibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany. Electronic address:
Allosteric regulation provides a powerful framework for modulating receptor signaling in both physiological and therapeutic contexts. The epidermal growth factor receptor (EGFR), a receptor tyrosine kinase frequently dysregulated in cancer, undergoes activation through conformational transitions that couple extracellular ligand binding to intracellular kinase signaling. Here, we explore how camelid derived VHH (variable domain of the heavy chain of a heavy chain-only)-antibodies can exploit this allosteric architecture to inhibit EGFR function.
View Article and Find Full Text PDFDiscovery of broadly neutralizing VHs against short-chain α-neurotoxins using a consensus toxin as an antigen.
MAbs
December 2025
Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.
Snakebite envenoming is a neglected tropical disease that afflicts millions of people globally, leading to substantial morbidity and mortality. Developing novel antivenoms, particularly recombinant antivenoms based on broadly neutralizing monoclonal antibodies, offers a promising strategy to address the challenge posed by venom variability. However, the extensive diversity of snake venom toxins across species and geographical regions makes this goal inherently complex.
View Article and Find Full Text PDFTargeting RAGE with Nanobodies for Molecular Imaging of Cancers and Alzheimer's Disease.
Adv Biol (Weinh)
June 2025
Shenzhen Kangning Hospital, Shenzhen Mental Health Center, Shenzhen, 518118, China.
The receptor for advanced glycation end products (RAGE) is a multifunctional cell surface receptor implicated in aging and the progression of chronic diseases, including cancer and Alzheimer's disease. Its interaction with advanced glycation end products (AGEs) promotes cellular stress and inflammation, underscoring the diagnostic and therapeutic relevance of targeting RAGE. In this study, we explored the potential of nanobodiessingle-domain antibodies known for high specificity, strong affinity, and deep tissue penetrationas molecular tools for RAGE-targeted applications.
View Article and Find Full Text PDFDaratumumab and isatuximab differentially affect CD38 detection on plasma cells in myeloma: Anti-CD38 nanobody (clone JK36) and CD319 combination improve flow cytometric identification of plasma cells after targeted therapies.
Br J Haematol
June 2025
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Inclusion of daratumumab and isatuximab in therapeutic regimens has improved outcomes in multiple myeloma patients. As these agents block CD38 detection, they may result in difficulties in flow cytometric (FC) identification of plasma cells (PCs). In addition, the heterogeneity of myeloma immunophenotype and the introduction of novel therapeutic agents necessitate FC panels with robust gating markers.
View Article and Find Full Text PDF